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Abstract: Biomarker-based predictive tests for subjectively asymptomatic Alzheimer’s disease (AD)
are utilized in research today. Novel applications of artificial intelligence (AI) promise to predict
the onset of AD several years in advance without determining biomarker thresholds. Until now,
little attention has been paid to the new ethical challenges that AI brings to the early diagnosis in
asymptomatic individuals, beyond contributing to research purposes, when we still lack adequate
treatment. The aim of this paper is to explore the ethical arguments put forward for AI aided
AD prediction in subjectively asymptomatic individuals and their ethical implications. The ethical
assessment is based on a systematic literature search. Thematic analysis was conducted inductively
of 18 included publications. The ethical framework includes the principles of autonomy, beneficence,
non-maleficence, and justice. Reasons for offering predictive tests to asymptomatic individuals are
the right to know, a positive balance of the risk-benefit assessment, and the opportunity for future
planning. Reasons against are the lack of disease modifying treatment, the accuracy and explicability
of AI aided prediction, the right not to know, and threats to social rights. We conclude that there are
serious ethical concerns in offering early diagnosis to asymptomatic individuals and the issues raised
by the application of AI add to the already known issues. Nevertheless, pre-symptomatic testing
should only be offered on request to avoid inflicted harm. We recommend developing training for
physicians in communicating AI aided prediction.
Keywords: autonomy; justice; population screening; preclinical; pre-symptomatic; machine learning;
explicability; informed consent
1. Introduction
The World Health Organization estimates that in 2050 three times more people will
be affected by Alzheimer’s disease (AD) than today and demands the development of
early diagnosis [1,2]. Screenings are considered suitable for this purpose. To cope with
the enormous financial and time-consuming effort of population-wide screenings, a two-
step strategy is currently being tested. Both steps apply machine learning (ML), a subset
of artificial intelligence (AI): first, identification of high-risk individuals on the basis of
socio-demographic or prescription data [3,4]; second, individual biomarker assessment in
high-risk individuals to identify eligible subjects for clinical trials with the future prospect
of delaying or alleviating the progress of AD in affected persons [5,6].
The technology of AI aided AD prediction is already at an advanced stage. The first
clinical AI decision support tool for predicting the progression from early-stage dementia
to AD was recently tested in a multicenter study [7]. The trend leads to train ML systems
on multi-feature datasets instead of assessing only one biomarker [3]. In addition to genetic
testing and detection of biomarker sets [8], neuroimaging is used most often in conjunction
with AI [9]. A recent model predicts AD 75.8 months prior to final diagnosis by using
neuroimaging and performs better than radiologic readers [10]. Accuracy, sensitivity, and
specificity when classifying patients with AD from healthy controls achieves almost the
maximum [11].
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Predicting the future onset of AD is accompanied by ethical challenges since there
is no disease modifying treatment available yet [12–14]. Nevertheless, early diagnosis of
prodromal AD is considered crucial for the well-being of individuals and society. Therefore,
an international expert group demanded guidelines for risk assessment in asymptomatic
subjects that can guide decisions on the application of screenings [15]. Although this topic
is relevant for all countries world-wide, little has been done in this regard. We will give an
example from Germany, because it is a result of major stakeholder consultations involving a
wide range of medical specialties, we are most familiar with the local situation, and want to
make it accessible for a non-German readership. In 2018, the German Medical Association
(GMA) issued a statement on the use of predictive tests for the risk assessment of AD [16].
The GMA does not recommend offering predictive tests to asymptomatic individuals that
have no familial AD background. Unfortunately, there is no justification for this conclusion
except: (a) lack of evidence on the validity of predictive tests and (b) the challenges of
informed consent. With the advent of AI aided AD prediction in asymptomatic individuals,
the matter becomes even more urgent, as Eric J. Topol warns, otherwise a prominent
supporter of medical AI [17]. Another multi-stakeholder project just underway is exploring
the ethical challenges of dementia prediction in Germany, but does not address AI aided
prediction [18]. This invites us to explore the ethical arguments related to AD prediction
through AI and highlight their implications.
Although there is a large intersection with traditional biomarker and genetic as-
sessment, the application of AI raises new ethical questions [19]. “Brain checks” for
asymptomatic individuals are especially ethically challenging due to the lack of a medical
indication [18]. A survey of the practice of AD prediction in 108 German hospitals shows
that biomarker-based risk assessment is already used in clinical practice [20]. Before AI
aided AD prediction is used for population-wide screenings as commentators demand [4],
it must be considered under which circumstances it should be offered to asymptomatic indi-
viduals given the chance that there are unintended negative consequences, which possibly
exceed the potential benefits for individuals and society. Similar ethical issues emerged in
the discussion about incidental findings in the case of genetic risk assessment [21–23]. This
debate can inform AI aided AD risk assessment. Incidental findings cannot be considered
as unexpected [24], as diagnosis is by nature explorative and arrangements need to be
made to provide adequate patient communication according to bioethical principles. Thus,
considering informed consent as meeting the demands for transparency and minimizing
foreseeable burdens are also crucial for the ethical assessment of AI aided AD predic-
tion [25]. Another debate from which our discussion can benefit are the ethical guidelines
for pre-symptomatic testing for Huntington’s disease, which have been used as an ethical
model for genetic testing for early-onset AD [12,26–28].
Pending questions can be discussed within the ethical framework of the four bioethical
principles: respect for autonomy, beneficence, non-maleficence, and justice [29]. We show
that this framework adds value to the discussion of the clinical application of AI aided
prediction. However, there is the new challenge of explicability that is specific to AI/ML
algorithms: due to technological peculiarities, physicians cannot explain to the patient
why the black-box algorithm predicts a severe illness, because of the algorithm’s opacity.
This has a significant impact on obtaining informed consent. Although explicability is
a major issue, recent reviews on the ethical and social implications of using predictive
modeling for AD found that it is not covered in the literature [19,30,31]. Our approach
differs from previous research on ethical implications of predictive modeling for AD as
we systematically discuss the demands and challenges of explicability in medical AI in
relation to the four established principles of biomedical ethics.
The new situation with the advent of medical AI does not obviate the already known
challenges for biomedical ethics; we identified a large intersection between previously
known ethical issues and those brought by the introduction of medical AI. In this paper,
we will focus on the interaction between asymptomatic individuals and physicians. This
interaction is the subject of our ethical analysis that aims to explore the arguments for and
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against offering AI aided AD prediction to asymptomatic individuals and their ethical
implications. With this, we contribute to the ongoing discussion on AD prediction by
offering an extensive assessment of the ethical landscape and highlighting the need for
future research on ethics and policy-making.
2. Materials and Methods
The assessment of the ethical arguments for and against AD prediction through AI is
based on a systematic literature search. The systematic search was conducted according to
the PRISMA statement as indicated in Figure 1 [32]. The included publications were exam-
ined by a thematic analysis resembling the method of “systematic review of reasons” [33].
This method consists of four steps: (1) Formulation of the review question and eligibility
criteria; (2) Identification of literature that meets the eligibility criteria; (3) Extraction and
synthesis of the data; (4) Deriving and presenting results to answer the review question. We
have slightly adapted this method to fit our research question: Which ethical arguments are
used in favor of or against offering AI aided AD prediction in subjectively asymptomatic
individuals?
Figure 1. Flowchart of bibliographic database searching resembling the PRISMA (2009) statement.
An initial search in PubMed with the search string ((“artificial intelligence”) OR (AI))
AND (alzheimer) AND (ethic*) yielded no significant publications (n = 76). Therefore,
we searched systematically in three bibliographic databases with five search strings to
obtain publications that elaborate, review, discuss or evaluate ethical arguments. The mix
of the databases PubMed, Cochrane Library, and PhilPapers was chosen on the grounds of
obtaining both clinically and ethically relevant arguments. The last search was conducted
Diagnostics 2021, 11, 440 4 of 17
on 19 November 2020. The eligibility criteria for including publications are: conceptual
studies, opinion pieces, qualitative research, original articles, and reviews in peer reviewed
journals. Publications in English, French and German language were included without
restrictions on publication date.
First, we gathered publications by a search in PubMed with search string 1 (“Alzheimer
Disease/diagnosis” [MeSH] AND “Ethics” [MeSH]) (n = 134). To complement this search
with less restrictive keywords, we secondly searched PubMed with the search string
2 (alzheimer*) AND (early diagnosis) AND (ethic*) (n = 173). Third, to provide an empiri-
cally grounded ethical analysis the evidence of the present diagnostic power of AI aided
AD prediction was collected through a search in PubMed with the search string 3 ((artificial
intelligence) OR (deep learning) OR (machine learning)) AND ((Alzheimer’s disease)) AND
((prediction) OR (diagnosis)) AND (review) (n = 117). Fourth, Cochrane Library has been
searched with search string 4 “Alzheimer” AND “diagnosis” within titles, abstracts, and
keywords (n = 34), but there was no systematic review yet on early diagnosis or prediction
through AI. Fifth, to gain more ethical and philosophical publications, we searched the
bibliographic database PhilPapers with the search string 5 “Alzheimer” (n = 430).
The searches yielded n = 888 records. A total of n = 844 were screened for titles and
abstracts after duplicates were removed. Exclusion criteria for eligibility were as follows:
validity studies on specific measures or tests (n = 39), studies on late-onset AD (n = 62),
studies on non-human subjects (n = 34), studies that do not deal with AI (n = 96), and
studies that do not deal with ethical arguments (n = 76). A total number of n = 18 eligible
articles were included in a thematic analysis that allowed to answer the research question.
Thematic analysis was conducted inductively by one reviewer to identify, analyze, and
report recurrent patterns of arguments in included publications [34,35]. The initial coding
was conducted by F.U. and reviewed by C.T. and F.St. The pooling of the data was carried
out in two steps: first, identified arguments have been assigned to overarching themes until
the level of abstraction was sufficient; second, reasons have been binary assigned to pro
and contra arguments. This process was conducted by F.U. and reviewed by C.T. and F.St.
until consensus was reached. The authors of the article have a background in medicine,
ethics, philosophy, and history of medicine. Because this study was interested in the
relation between asymptomatic individuals and physicians, the pooling of the qualitative
data was conducted to address ethical implications both from an individual and a societal
perspective.
3. Results
Examined publications include original contributions, questionnaire surveys, focus
group studies, ethical evaluations, a strategic road map for research, and reviews (Table 1.).
To some extent the ethical evaluation depends on use case, because rights and duties
may vary depending on the use context for the involved moral agents (Table 2.): e.g.,
researchers towards participants (research ethics); physicians towards patients in clinical
treatment (clinical ethics); governments towards citizens in society (public health ethics).
The use cases have been built by pooling additively from different publications, because
not all use cases were mentioned in one publication. We present an extended list of
ethical arguments for and against offering AD prediction to asymptomatic individuals in
Tables 3 and 4. In what follows, we clustered the most common ethical issues into three
groups to facilitate a better overview: (a) individual benefits and disadvantages, (b) social
benefits and disadvantages, and (c) right to know vs. right not to know.
Diagnostics 2021, 11, 440 5 of 17
Table 1. Included literature on the ethical arguments for and against offering AI aided AD prediction to asymptomatic
individuals.
Authors Title Type of Study Date
Smedinga, Tromp, Schermer,
Richard
Ethical Arguments Concerning the Use of
Alzheimer’s Disease Biomarkers in Individuals
with No or Mild Cognitive Impairment: A





Review of the Ethical Issues of a




Expanding engagement with the ethical
implications of changing definitions of
Alzheimer’s disease
Correspondence (conceptual) 2017
Whitehouse Ethical issues in early diagnosis and preventionof Alzheimer disease Original Article (conceptual) 2019
Vanderschaeghe, Vandenberghe,
Dierickx
Stakeholders’ Views on Early Diagnosis for
Alzheimer’s Disease, Clinical Trial Participation
and Amyloid PET Disclosure: A Focus Group
Study
Focus Group (qualitative) 2019
Erdmann, Langanke The Ambivalence of Early Diagnosis—ReturningResults in Current Alzheimer Research
Risk-Benefit-Assessment
(conceptual) 2018
Schermer, Richard On the reconceptualization of Alzheimer’sdisease Original Work (conceptual) 2019
Hughes, Ingram, Jarvis, et al. Consent for the diagnosis of preclinical dementiastates: A review Review 2017
Davis Ethical issues in Alzheimer’s disease researchinvolving human subjects Original Work (conceptual) 2017
Schweda, Kögel, Bartels, Wiltfang,
Schneider, Schicktanz
Prediction and Early Detection of Alzheimer’s




Stites, Milne, Karlawish Advances in Alzheimer’s imaging are changingthe experience of Alzheimer’s disease
Narrative Review
(conceptual) 2018
Angehrn, Sostar, et al.
Ethical and Social Implications of Using
Predictive Modeling for Alzheimer’s Disease
Prevention: A Systematic Literature Review
Systematic Review 2020
Ivanoiu, Engelborghs, Hanseeuw Early diagnosis of Alzheimer’s disease (with theannouncement of the diagnosis) Original Work (conceptual) 2020
Mattsson, Brax, Zetterberg To Know or Not to Know—Ethical Issues Relatedto Early Diagnosis of Alzheimer’s Disease Original Work (conceptual) 2010
Frisoni, Boccardi, Barkhof, et al. Strategic roadmap for an early diagnosis ofAlzheimer’s disease based on biomarkers Whitepaper 2017
Ebrahimighahnavieh, Luo,
Chiong
Deep learning to detect Alzheimer’s disease
from neuroimaging: A systematic literature
review
Systematic Review 2019
Graham, Lee, Jeste, et al.
Artificial intelligence approaches to predicting




Prevalence and Diagnosis of Neurological
Disorders Using Different Deep Learning
Techniques: A Meta-Analysis
Systematic Meta Review 2020
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Table 2. Use cases for offering AD prediction to asymptomatic individuals.
Use Cases Ethical Assessments Source
(1) research
protected by good clinical practice research frameworks,
ethics approvals by ethics committees, and informed
consent
[15,19,36]
(1a) symptomatic patients actively seeking support benefits of early detection outweigh potential adverse effects [37]
(1b) asymptomatic volunteers which consent to
predictive testing
potential adverse effects overweigh the benefits, therefore
restrictive disclosure policy according to the “principle of
caution”
[37]
(2) screening everyone “turning everyone into patients” and “patients-in-waiting” [31,38]
(3) screening those with known risk factors partial exclusion of patients and “patients-in-waiting” [31,38]
(4) psychological screening before screening partial exclusion of potential patients [31]
(5) voluntary access to screening for everyone considered ethically justified to disclose biomarker resultson request [31,39]
(5a) symptomatic patients actively seeking support benefits of early detection outweigh potential adverse effects [37]
(5b) asymptomatic patients actively seeking support considered ethically unjustified to disclose biomarker results [39]




resolving uncertainty of one’s risk is beneficial when it brings clinically
meaningful information and the subject is willing to know his risk or
diagnosis
[19,31,37]
knowing one’s risk enables future planning [19,20,31,37,38,40]
knowing one’s risk enables promotion of research and control of the
disease’s progression [19,20,38]
knowing one’s risk enables change of unhealthy lifestyle [37,41]
Right to know
good communication requires a physician to determine whether an
individual wishes disclosure based on personal preferences [19,30,38,41,42]
respect for the individual’s autonomy and empowerment [37,41]
clarity, informing family members, and planning for the future [40,43]
Slippery-slope-argument voluntary screening is justified since commercial genetic testing for ADis already available [31,36]
Economy
cost-effectiveness is a requirement for predictive tests and future
hypothetical preventive treatment, but opinions are divided whether
tests would save money or increase costs
[19,20,31]
restriction of tests beyond research use cases that are used for profit in
individuals for whom a risk assessment is not indicated [15]





knowing one’s risk or diagnosis does not alter the disease [19,30,31]
general screening is only considered useful if effective treatment options are available [19,20]
predictive testing is only seen as ethically acceptable in research because predictive
value is unclear and preventive measures are not available [19,38]




although predictive AI systems have a high accuracy, there is no social
consensus about which predictive power is sufficient [3,9,31,44]
no clinical use before regulatory approval because of the risk of false-negative
and false-positive diagnoses, no consensus about sufficiency of predictive
power, amyloid cascade hypothesis is contested in research, patients may not
understand the predictive value and undergo therapeutic misconception
[12,30,31,38,40]
false-negative diagnoses may lead to false reassurance and exclusion from
treatment or clinical trials [15,31,37]
false-positive diagnoses may lead to over-diagnosis, over-treatment,




avoidance of psychosocial harm because of distress, anxiety, remaining
post-testing uncertainty, possible false-positive or false-negative diagnoses,
stigmatization (public stigma, self-stigma, spillover stigma), discrimination in
health insurance and at work
[19,20,30,31,38,40,41,
45,46]
avoidance of harm to third parties because of family burdens, social burdens
(isolation, discrimination, and social rejection) [40,41,45]
avoidance of harm to subjects and third-parties because of “rational suicide”
based on financial reasons and to reduce family burden [30]
Right not to know
wish not to know because of anxiety and disease modifying treatments are not
available [19,30,40,41]
avoidance of forced information because it violates respect for autonomy [20]
Explicability
patient’s different degrees of understanding the disease and the uncertainty of
preclinical risk assessment entail a challenging communication of diagnosis or
risk assessment
[12,30,31,40,45]
demand for the transparency of the “diagnostic decision” due to involvement
of AI/ML (machine learning) systems and black box algorithms [3]
demand for governance models for patient’s data, data security, infrastructure






need for international agreements on the protection of subjects that underwent
a biomarker test like in the case of
genetic privacy
[36,45]
worries that health insurances deny coverage or
charge higher premiums [19,20,30,36,45]
worries about employment discrimination, exclusion from medical decision
making, or the withdrawal of one’s driving license [3,20,30,45,46]
Training demand for structured training of physicians to counsel patients about AI/MLsystems [15,45]
Guidelines and
standardization
demand for guidelines about information and
disclosure practice [15,20,36]
demand for standardization of test methods, threshold values, data protection [15,20]
3.1. Individual Benefits and Disadvantages
Benefits of AD risk disclosure can derive from resolving the uncertainty of one’s own
AD risk if it brings clinically meaningful information and the subject is willing to know
the risk [19,31,37]. Benefits can also derive from future planning in regard to potential
caregivers, housing situation, family life, adjustment of insurance, financial planning, and
end-of-life care [19,20,31,37,38,40]. Promotion of research and improved control of the
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disease’s progression are seen as benefits [19,20,38]. There is the opportunity to change
unhealthy lifestyles [37,41]. In case of symptomatic patients actively seeking support in a
research setting, the benefits of early detection outweigh potential adverse effects [37].
A reason against offering predictive testing is the lack of a disease modifying treatment.
Knowing one’s risk does not alter the disease [19,30,31]. A general screening (second use
case in Table 2) is only considered individually useful if effective treatment options are
available [19,20]. Predictive testing is held to be ethically acceptable only in research (first
use case in Table 2) because the predictive value is unclear and preventive measures are
not available [19,38].
Without disease modifying treatment the risks of a disclosure are potential psychoso-
cial harms, distress, anxiety, remaining post-testing uncertainty, possible false-positive
or false-negative diagnoses, stigmatization (public stigma, self-stigma, spillover stigma),
and discrimination in health insurance and at work [19,20,30,31,38,40,41,45,46]. Since a
disclosure also affects the family and potential caregivers, unanswered questions remain
regarding social burdens like isolation, discrimination, and social rejection [40,41,45]. Pa-
tients may consider a “rational suicide” based on financial reasons and to reduce family
burden [30]. It is unknown how much support an individual needs after learning about
a diagnosis of preclinical AD [45]. In case of asymptomatic volunteers who are tested
in a research setting, the potential adverse effects overweigh the benefits and therefore a
restrictive disclosure policy should be applied according to the “principle of caution” [37].
It is considered unethical to disclose biomarker results to asymptomatic patients attending
a memory clinic [39].
3.2. Social Benefits and Disadvantages
The cost-effectiveness of both predictive tests and future hypothetical preventive
treatment is considered a requirement for offering predictive tests, but opinions are divided
regarding whether tests would save public health resources or increase costs [19,20,31].
Tests outside of a research setting that are used for profit in individuals for whom a risk
assessment is not indicated should be limited [15]. Policy-makers may, however, have
an interest in performing random tests or general screenings to gather information about
changing trends in order to facilitate long-term planning. Here the interests of individuals
and policy-makers may conflict [4].
In terms of social rights, there are no international agreements on the protection of
subjects that underwent a biomarker test as in the case of genetic privacy [36,45]. Regula-
tions to protect social rights and privacy are demanded, because worries exist that health
insurances deny coverage or charge higher premiums if a diagnosis for AD is in the medical
record [19,20,30,36,45]. Further concerns regard the protection against discrimination in
employment, exclusion from medical decision making, or the withdrawal of a driving
license without an adequate alternative to guarantee mobility [3,20,30,45,46].
3.3. Right to Know vs. Right Not to Know
There are significant differences in personal preferences in undergoing predictive test-
ing [42]. People have the right to know the risks, but respect for autonomy requires a physi-
cian to determine whether or not an individual wishes to receive disclosure [19,30,38,41].
Offering tests and disclosing test results is in most cases considered to be in accordance
with the respect for the autonomy of a person and a way of empowerment [37,41]. Reasons
for wanting to know one’s biomarker status are the need for clarity, informing family
members, and planning for the future [40,43].
The right to know stumbles against two major obstacles: the accuracy of diagnosis
and the (in)explicability of results. Although the accuracy of predictive AI systems has
significantly increased in recent years [3,9,44], there is no consensus about which predictive
power is sufficient [31]. A poor sensitivity (false-negative diagnoses) might lead to false
reassurance and exclusion from treatment or clinical trials; a poor specificity (false-positive
diagnoses) might lead to over-diagnosis, over-treatment, inappropriate inclusion in clinical
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trials, and invasive biomarker testing that can be harmful [12,15,31,37]. Overall, the amyloid
cascade hypothesis, on which biomarker assessment rests, is contested in research [38].
Persons undergoing testing may not understand its predictive value and are subject
to therapeutic misconception [30,40]. Communicating an AD diagnosis or risk assessment
is considered challenging due to different degrees of understanding of the disease and
the uncertainty of preclinical risk assessment [12,30,31,40]. Interview studies show that
persons who have learned their elevated biomarker level also understand that their risk of
developing AD is increased but uncertain, however, they wished to know how a dimen-
sional biomarker was turned into the categories “elevated” or “not elevated” [45]. This
wish cannot be met with AI, because these black box systems only distinguish between
“has that condition” or “does not have that condition” [3]. Therefore, an explainable AI is
demanded that is transparent in its “decisions” [3]. Further challenges are accountability,
algorithm bias due to insufficient training data, application of passive surveillance tools,
and regulatory approval [3]. Challenges are seen in the paradigm shift to so-called “desktop
medicine”, where individuals learn about their health from test results and not based on
symptoms [31].
There are also strong arguments for supporting a right not to know. Reasons for not
wanting to know one’s biomarker status are anxiety about AD and that disease modifying
treatments are not yet available [19,30,40,41]. According to a survey in German hospitals,
81% of physicians acknowledge the patient’s right not to know of the individual biomarker
status, but disclosure practice shows that 75% of physicians do always communicate results
of predictive testing [20]. Furthermore, 10% communicate results only on request and
20% communicate results only in combination with psychological consultation [20]. On
the other side, a culture of withholding dementia diagnosis is described which argues in
favor of non-maleficence [30]. This may have adverse effects in terms of being paternalistic,
although a physician may have good intentions by withholding information [37]. Study
participants have the ethical right to a full disclosure upon request based on the principle
of autonomy [19,37].
4. Discussion
We discuss the ethical implications of AD diagnosis in relation to the four bioethical
principles. The discussion of the respective arguments in Tables 3 and 4 is assigned to one
of the following four sections, each addressing a bioethical principle. In the cases where an
argument can be discussed under more than one principle, we opted for the principle that
facilitates the most accessible description of the ethical dilemmas. Under the perspective of
autonomy, we discuss arguments regarding the right to know vs. the right not to know,
elements of informed consent, adequate counseling when AI is involved, and the need for
explainable AI. Under the perspective of beneficence, we discuss arguments of improved
precision and reduced human errors, but also the practical hindrances of implementing AI
in the diagnostic process. Under the perspective of non-maleficence, we discuss the harms
that can be caused by AD prediction, threats of automation bias and algorithmic bias, and
the question of liability of black box systems. Under the perspective of justice, we discuss
arguments concerning access to healthcare, distributive justice, arguments concerning
cost-effectiveness, and the tensions between individual and societal needs.
To complement the discussion of our results, we deem it helpful to consider the
already developed ethical guidelines for pre-symptomatic testing for Huntington’s disease.
These can be used as an ethical model for genetic testing for early-onset AD [12,26–28]
and therefore can serve as discussion basis for AI aided AD prediction. These guidelines
foresee that [47]:
1. The test should be voluntary and based on informed consent.
2. The test should be offered with proper counseling and professional support.
3. The test should only be available to mature adults.
4. The test results should not cause discrimination.
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5. Testing should be delayed if there is evidence that the results will lead to psychosocial
harm.
6. The test results are confidential and the property of the individual.
Further insights are gained from the literature on explicability.
4.1. Autonomy
We found that there is a discussion about whether offering predictive testing to
preclinical individuals may violate their autonomy [30,46]. The literature distinguishes
between two scenarios: a patient who autonomously requests a test, and one who is offered
a test although he does not request it or show any desire to acquire such information [48].
Patient’s autonomy may be violated, if he is involuntarily tested or informed about the test
results [49]. Respect for the patient’s autonomy includes the negative duty not to impose
unwanted information and the positive duty to disclose information and actions that foster
decision making [50]. Patient’s autonomy can be respected by informed consent and can be
violated by withholding pertinent information or ignoring a refusal of medical intervention
or diagnosis.
We found that the right to know is a central argument in favor of predictive testing [19].
The right to know is a prerequisite to allow individual choice for patients, to respect
individuals as autonomous subjects, and to facilitate future planning. Conversely, the right
not to know has originally been justified to defend a person’s interest in not spoiling a
certain element of surprise, for example concerning the gender of one’s offspring, or more
recently to allow the reasonable enjoyment of certain foodstuffs without the imposition of
details of its production or content [51]. In our case, the right not to know is a response to
the predictive power of new diagnostic methods, which predict a risk of serious disease in a
context where no effective treatment is available [19,30]. It is an exception to the physician’s
duty to inform [52]. Obtaining assent to predictive testing and disclosing of the results
honors the autonomy of patients and involves them in the decision process [53]. For various
reasons, a patient may not want to know the result of a test even if he initially asked for it,
because, e.g., family members or potential caregivers are often present when disclosing
a diagnosis [54]. A patient’s values and wishes should be the primary determinant for
disclosure decisions, whether they coincide with their caregiver’s wishes or not [53].
Empirical data show that most people want to know whether or not they will develop
AD [55]: more than half (56.1%) want brief information and immediate referral to a family
practitioner or a specialist. Only 9.8% want no information because they claim to have
a right not to know. These results concur with earlier evidence according to which most
patients want to know the truth about their dementia diagnosis, although they feel upset
after disclosure [56]. At the same time, these results clearly indicate that physicians should
not assume that all patients want to receive such information. Two provisions apply: first,
consistent with the principle of beneficence, the physician may educate the patient about
the benefits of advanced planning for autonomy in the event of becoming incapacitated [29].
Second, the right not to know should not be used to shield patients from knowledge about
the existence of such diagnosis possibilities [57]. Information generally supports autonomy.
A failure to inform about such tests may jeopardize future planning capacities to protect an
interest that can be considered as of second order.
Another determinant for disclosure decisions is the psychological state of the patient. It
has been argued that postponing diagnosis disclosure is acceptable if the patient is in a bad
psychological state [58]. In accordance with the principle of non-maleficence, the physician
has to consider the patient’s cognitive and social resources as well as psychological coping
skills [53]. We argue that postponing diagnosis disclosure is ethically appropriate if the
principle of non-maleficence weighs heavier than the respect for temporary autonomy at
the physician’s reasonable discretion. A test may not be in the patient’s best interest in
times of strong distress since the results would not change treatment or outcome [28]. A
physician’s duty to immediately warn a patient in order to prevent harm may not apply,
because the disorder is inevitable and no disease-modifying treatment is available.
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AI assisted diagnosis suggests an enormous challenge regarding the informing of
patients about results and future action. The limitations of the test results must be inter-
preted and communicated to the patient, especially regarding the accuracy, sensitivity and
specificity of the given AI aided diagnostic tool [30]. An emerging aspect when applying
AI aided diagnosis for preclinical patients is a new type of counseling, which is comparable
to traditional genetic counseling [23]. Patients should be informed via “digital counseling”
about the AI system that was involved in the process of prediction, risk assessment or
diagnosis. There are promising attempts to overcome such communication challenges
by assisting the information process with graphics. For instance, explainable convolu-
tional neural networks as diagnostic tools for early detection of AD are being developed
by visualizing certain patterns [3,10,59]. Activation maps point to the relevant areas in
neuroimaging data and thereby can provide intuitive understanding of model output for
clinical users. A simplified and visually enhanced version of these maps can be shown to
patients to facilitate the information process.
Protocols to safeguard patient autonomy and privacy may slow down technology
developments. The challenge is that machine learning algorithms can learn continuously
when new data is included. Although learning systems are desired because they increase
diagnostic accuracy, this may conflict with existing regulations for “Software as a Medical
Device” that aim to restrict the transfer of sensible data [60]. Once the data is shared by both
the training and testing sets, the new data influences future classification decisions [61].
Thus, a systematic and controlled process of data curation is needed for “Software as a
Medical Device”. Technology developers and collaborating physicians may have a conflict
of interests when it comes to technology optimization that needs to be communicated
to patients to find out whether they still give informed consent to participate in this
experimental optimization process.
We conclude that it is ethically appropriate to offer predictive testing to persons in case
they ask for it, because this is not imposed information, as long as they are in a condition to
assess the communicated information. Informed consent remains the guiding principle for
both performing predictive testing and for disclosing results. Because informed consent
includes voluntariness, competence to decide, information disclosure, and understanding
by those receiving the information, all these aspects have to be secured in case AI is
involved. However, currently there is an ongoing debate as to whether or not patients have
to be informed that AI is involved in the diagnosis or treatment [62]. This question is still
not settled and must be addressed by future legal and ethical inquiries.
4.2. Beneficence
As a general ethical guideline, early diagnosis of AD must be beneficial to the pa-
tient, otherwise the test should be avoided. Beneficence requires the prevention of harm,
providing benefits, and balancing benefits against risks and costs [29]. There are several
areas in which early risk assessment of AD may be beneficial toward patients: exclusion of
other causes for cognitive impairment and planning for the future [63]. An early diagnosis
enables patients and their families to understand the disease, to decide on emerging finan-
cial burdens, and to arrange for the future needs and care of patients [8]. To this end, the
World Health Organization, Alzheimer’s Disease International and several national public
health authorities advocate early diagnosis in their dementia action plans [12]. Extensive
counseling and appropriate education have shown positive outcomes following predictive
testing [64].
AI aided diagnostics could help reduce human errors. It is unfortunate that there
might be a reluctance among physicians to use AI aided diagnostic tools on several
grounds [3,65–67]: first, black box systems are not transparent in their “decisions”; sec-
ond, there might be technical and financial barriers to integrate these systems into clinical
workflow; and third, there is the need to ensure information privacy with proper reliable
data labeling, because risk assessment produces sensible data. The principle of beneficence
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invites at least an exploration of AI aided diagnosis as a method to improve precision and
reduce errors.
4.3. Non-Maleficence
The overall goal of the principle of non-maleficence is not to cause harm to patients by
a medical intervention or diagnosis [29,50]. We found that predictive AD testing has been
considered unethical because no effective prevention and disease-modifying treatment
is available [19,68]. This holds true in the present research setting in which volunteers
obtain disclosure of their risk assessment [37,39]. Disclosing a diagnosis for AD can cause
harm to patients [19]: there is an increased risk of depression, psychiatric hospitalization,
stigmatization [69], and suicide as in other neurological diseases with a not favorable
prognosis [26,70], e.g., Huntington’s disease [71,72]. Additionally, potential consequences
of learning information about AD risk on life and health insurance coverage, employment,
driving license and implications for an individual’s social position and identity have to
be considered [30,46]. Moreover, although there are lower suicide rates in the long run of
diagnosed dementia patients compared to control groups with no neurological disorder,
the death by suicide ratio is three times higher than in controls during the first month
after diagnosis [70]. We conclude that it depends on the use case whether possible adverse
effects of disclosing results of predictive testing overweigh the benefits of knowing one’s
risk. Adequate counselling may mitigate negative effects and therefore needs to be part of
the diagnosis procedure.
A physician who provides AD prediction through AI must be able to explain on
which grounds the algorithm came to its decision. Since physicians are always responsible
for a medical procedure [73], intelligibility is crucial, because diagnostic systems have to
be explainable, interpretable, understandable, and transparent in terms of their decision-
making properties [74]. In terms of accountability, liability is an unsolved challenge.
In a joint European and North American multi-society statement on the ethics of AI in
radiology, automation bias and liability of black box systems have been addressed as the
most important ethical challenges [73]. Automation bias leads humans to prefer machine-
generated decisions over those of humans. The question is to what degree physicians can
delegate the task of diagnosing to autonomous systems without exposing themselves to
increased liability for malpractice in case the system makes an error [75]. Thus, there is
a need for different liability models for different use cases and for a risk liability system.
The medical societies state that physicians will remain ultimately responsible for patient
care [73]. The question arises whether AI aided diagnosis is a mere second opinion [76],
and if it is, why it should be used given all its disadvantages such as costs of development
and implementation, limited explicability and liability questions [65]. Advantages like cost-
effectiveness once installed, time-saving, high accuracy, and the fact that they outperform
physicians in diagnosing may lead to their implementation [77,78]. Commentators outline
future prospects in which delegating time-consuming activities to autonomous systems
enables physicians to spend more time on their core tasks [79]. To meet the principle of
non-maleficence, the advantages of AI need to benefit the individual patients and overall
lead to less hazards. An overemphasis on cost saving may leave responsibility issues
unaddressed and undermine obligations to adequately inform patients.
4.4. Justice
Justice in our case refers to three distinct principles: firstly, to the principle that like
cases should be treated alike, secondly, to distributive justice demanding a fair, equitable
and appropriate distribution of health care in society [29,50], and thirdly, to assess whether
our innovation system contributes to structural injustices by continuing to disadvantage
historically marginalized groups [80].
Access to dementia diagnostics is limited by two types of resources. First, the number
of physicians in the specialties of geriatrics, neurology, and geronto-psychiatry will be
insufficient, because it is expected that the number of AD cases will increase [8]. Second,
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cost-effective and accurate diagnostic tools are needed. Since neuroimaging is expen-
sive, cerebrospinal fluid analysis is invasive, and neuropsychological assessment is time-
consuming, the cost-effectiveness of neuroimaging could be improved by AI [3]. However,
there are worries about the disparities in access to AI aided dementia diagnostics since
smaller hospitals and academic departments may lack the technology, skills, and resources
to manage complex AI systems, or these systems are proprietary as they are developed
by large academic or private health care entities [73].When the accuracy of prediction by
AI aided neuroimaging outperforms cheaper diagnostic tools like assessment of speech,
gait, blood, and electroencephalography, then its application should be considered. Efforts
to expand access to AD diagnosis still need to keep in mind that providing adequate
information and counselling is part of the diagnosis and should not be sacrificed under the
excuse of making diagnosis more widely available.
There are ethical tensions between individual and societal needs when it comes to AD
diagnosis. The limitation of health care resources does not permit AD diagnosis to satisfy
mere individual curiosity. Conversely, while an individual may insist on the right not to
know by referring to autonomy, from a societal perspective there are several reasons to
know who may develop AD, some backed by the principle of justice. Insurance companies,
lending banks, employers, participants in road traffic, as well as family and marriage
partners may need to adapt their future behavior and policies [30,46]. Governments may
need to carry out population wide studies to assess future health needs and thereby secure
sufficient funding and health professionals for future needs. Massive refusal to test will,
however, not allow governments to make the necessary arrangements for an eventual
sharp increase in care cases which, particularly in welfare states, is their obligation. As
long as citizens agree on guaranteeing the common good of universal healthcare coverage
protection, they need to do their share in establishing such a good. This may include
consenting to randomized governmental testing. When such tests are done, it is unclear
whether or not identified at-risk individuals may be contacted: on the one side, there is
an ethical conflict between respecting the right not to know and the potential harm of
disclosure of being an at-risk subject. As these tests may disclose information that can
be important to individuals, a minimum level of diagnosis disclosure is unavoidable to
facilitate future planning. On the other side, there is the societal need for participants in
clinical trials and drug development studies. We conclude that the respect for autonomy,
the right not to know, and the principle of non-maleficence must be weighed with societal
needs for knowing who will develop AD in the future.
5. Conclusions
From an ethical point of view, it is crucial that predictive testing is safeguarded by
ethical principles which serve the needs both of individuals and society. In a given clinical
case, the principles and respective arguments can guide decision making by weighing
the principles against each other. At the individual level, the most important principle
is the respect for autonomy, which can be secured by determining whether a subject
has the wish to undergo predictive testing or not. As a general guideline and given the
present technological, regulatory, and ethical circumstances, predictive testing should
only be offered to asymptomatic individuals upon request in a research use case, which
is protected and regulated by research ethics. The risk of causing psychosocial harm by
disclosing test results must be as small as possible and the limits of accurate prediction
must be communicated to whoever requests a predictive test. Despite the individual risk,
governments need to inquire about the level of disease prevalence to make the necessary
arrangements for future social welfare. The ethical dilemma is that the test produces
clinically and socially useful information, while there is no disease modifying treatment.
Therefore, the ethical appropriateness of population-wide screenings that apply AI/ML
algorithms to identify at-risk individuals is questionable at present.
The future prospect is to focus on preventive strategies and to improve ethical training
to provide proper counselling. Because we still lack international standards and guidelines,
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the literature advocates the need for structured training in communicating diagnoses, and
guidelines for counseling about the risks and benefits of testing, as well as for disclosure
practice. Because we found analogies in the literature to other neurodegenerative diseases,
helpful guidelines may be developed by translating, adapting, and modifying guidelines
for these conditions which can be diagnosed in an asymptomatic state. Counseling is
considered crucial for the process of informed consent, the patient’s right (not) to know,
and avoiding harm. This addresses the competency of neurological, geriatric, geronto-
psychiatric, and radiological associations to develop standards for counseling on AI aided
diagnosis. We still need research in what this means specifically in the case of AD prediction
in asymptomatic individuals through AI.
We found that patients undergoing biomarker assessments want to know what it
means to have an “elevated” biomarker status. Here, we also need more research concern-
ing two ethical dimensions. Firstly, as a matter of transparency it has to be disclosed that AI
systems are deployed for prediction. Secondly, respect for autonomy demands explicability.
It is ethically necessary to develop explainable AI systems for future clinical applications.
These two dimensions are crucial to build trust within the interaction between patients and
physicians. Only if patients trust both the oversight of physicians and the robustness of
AI aided prediction, then offering it to asymptomatic individuals can succeed. For future
clinical application, we recommend the adaptation of ethical training for physicians in
communicating AI aided prediction by drawing on the experience in diagnosing other neu-
rodegenerative diseases. The training should incorporate the challenges of transparency
and explicability in securing adequate informed consent.
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